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of 60 were followed up to August 1996 to evaluate the impact of estrogen
therapy on target lesion revaacularization. Eatrogen therapy was continued
throughout the follow-up (FU) period. Between the two groups, there was
no significant difference in age, incidence of coronaty risk factors (hyperten-
sion, diabetes mellitus, hypercholesterolemia and smoking), LVdysfunction,
incidence of multiveasel disease, lesion morphology, vessel site stented and
number of atents per vessel or types of stent (Cook vs. JJIS). The long-term
outcomes are as follows:
Estrogen (n= 62) No Estrogen (n =55) p Value
FU davs 556 & 2S4 516 + 267 ns
i+ci;;intengina 2 (3”/0) s (15%) 0.04
Revascularization 12 (19%) 24 (44°/0) 0.0065
(PTCA and CABG) Death O 1 ne
FU angiograms were obtained only in 26 out of 62 in estrogen treatment
group with angiographic restenosis of 50% and 26 out of 55 in no estrogen
treatment group with restenosis of 85%.
Conclusions: Estrogen replacement therapy in post menopausal women
reduces angina and target lesion revascularization after intrecoronary atent-
ing. Further substantiation by large randomized studies is needed.
m1059144 OptimalCoronaryStentinginDiabetice:A ViabiePercutanaouaAlternativeto CardiacSurgery
F.V.Tilli, D. Aliabadi, T. Bowera, ‘M.M. Shoukfeh, M. Spybrook, R.D. Sefian.
William Beaumont Hospital, Royal Oak, Ml, USA
Diabetics have significantly higher ratas of target vessel revascularization
(TVR) compared with non-diabetics following percutaneous intervention.
Earlier studies have reported TVR rates > 50% in diabetics despite use
of intracoronafy atents. Recent randomized studies have sugge6ted that
diabetics with multi-vassel coronaIy disease fare better with surgical revas-
txrlarization. In the era of optimal coronary stenting, however, it may be
possible to minimize the need for TVR in diabetics, thareby making percuta-
neous revascularization more attractive. We assessed 9 month TVR in 316
consecutive patients stented between 11/94and 6/95, 81 of whom were dia-
betic. All stents were implanted using routine high pressure post-dilatations.
Diabetes was a strong predictor of TVR, necessary in 24/61 (W%) diabetics
vs. 36/234 (15%) non-diabetics, (p= 0.008). Recurrentangina prompted TVR
in 57/60 (95%) of cases.
Conclusions: Diabetes increases the likelihood of need for TVR two-fold
compared with non-diabetics. Despite this, use of optimal stenting technique
can result in mora acceptable restenosis rates compared with early stent
experience in diabetics. Whether percutaneous revascularization employing
optimal stenting technique compares favorably with surgery for diabetics with
multi-vessel coronary disease requires further investigation.
m1059145 NoExcaaaMotteiityAfterCoronaryAngiopiaetyin Diabetic Patienta with Multiveaael Dieeaee
after Prior Bypaaa Surgery
E. Frantz, P. Pfautsch, S. Mr%ldel,E. Fleck. Cardiology, Virchow C/inic,
Humboldt University and German Hear?Institute, Berfin, Germany
Recently an alert has been issued, that patients (pts) on drug treatment for
diabetes mellitus with multivessel CAD should not be treated by PTCA be-
cause of increased mortality compared to corona~ bypass surgery (CABG).
We investigated, whether this also is relevant for pts with recurrent ischemia
after prior CABG surgery.
n = 489 pts. (46.6 + 44 months after CABG) were treated by PTCA
(n = 438) or”Re-CABG (n = 51). Diabetes was present in 99 pts (20.2%),
(18.9% in PTCA; 31.4% in Re-CABG-groupa, resp.). During follow-upof 32.0
+ 25.2 months, 44 pts. died (30 in PTCA-group, 14 in Re-CABG-group).
3-yr-Mortality was 37.4% in diabetic pts. in Re-CABG-group, 25.7% in non-
diabetics in Re-CABG-group, 7.2% in diabetics in PTCA-group and 7.4%
in non-diabetics in PTCA-group. Cox hazard analysis identified diabetes as
risk factor for death with x 1.43 rel. risk (p < 0.007) in all patients, Survival
Cuwes:
Conclusions: In this series, redo bypass surgery resulted in higher death
rates than angioplasty for diabetic patients as well as for non-diabetic pa-
tients. Nevertheless, irrespective of treatment ragimen, diabetes is a risk
factor for fatal adverse cardiac events at follow-up.
11059-1461 CoronaryStentingintheDiabeticPatients:~ariy
and Follow-up Reeulta
H. Yokoi, H. Noaake, T. Kimura, T. Tamura, Y. Nakagawa, N. Hamasaki,
M. Nobuyoshi. Kokura Memorial Hospital, Kitakyushu, Japap
Balloon PTCA in diabetic (D) patients (pts) has been associated with iess
favorable outcomes due to their increased incidence of restenosis and pro-
gression of disease. To assess whether Palmez-Schatz (PS) stent iaa useful
alternative to bailoon PTCA in D, immediate and follow-up (FU) results were
analyzed in consecutive 931 pts received PS implantation and compared D
pts with none-diabetic (ND) pts. Clinical success was defined as < 50% resid-
ual stenosis without death, CABG, Q-wave Ml. FU quantitative angiography
was obtained from 819 pts (66Y0)after 6 months or earlier when indicated
by symptoms. Clinical FU data was obtained after 12 months. Event-free
survival was definsd as free from death, Ml, CABG, target and new lesion
PTCA at FLL
D (N = 2s3) ND (N = 66s)
.,
Multi Vsseel*/Poor LV* (OA) 69/18 57/12
Calcification (%VLL (mm) 24/12,5 1S/11.8
Reference diam’eter(mmj 3,24 + 0.65 3.23 + 0.84
Pre MLD (mm) 0.76 + 0.46 0.76 + 0.47
Post MLD (mm) 2.66 + 0.50 2.88 + 0.49
Clinical Success (%) 97 95
Death/Ml/CABG (%) 0.4/1 .1/0.4 2.3/1 .5/1.2
Thromboeia (%) 0.s 1,s
Bleeding complication (%) 4.6 4.9
FU MLD* (mm) 1.93 * 0.91 2.06 l 0.82
Binaiy restenosis*~LR (%) 29/19 22/15
Event Free Suivivsl (%) 32 27
*p <0.05, MLD = minimal lumen diameter, LL = iesion length
Conclusion: 1) PS stent implantation can be performed in D pts with the
acceptable complications despite unfavorable clinical environment. 2) But
restenosis following stenting in D is significantly higher because of greater
late loss, probably reflecting more aggressive intimal hyperplasia.
I1059-147I Corona~stentingDUringEmergency
Angioplasty in High-Risk Myocardial Infarction:
Data From a Multicenter Registry
G.Steffenino 1,S. Chierchia, A. Fontaneili, L. Niccoli, S. Repetto, G. Risice
for the RAI Regisby Investigators. ‘ Di!z of Cardiology Ospeda/e S. Croce,
Cuneoj /fa/y
Use of coronary atents (CS) during amergency angioplasty (EM-PTCA) in
acute myocardial infarction (AMI) is controversial. The l-year RAi registry
was started in November ’95 to monitor the pariormance, in-hospital and
6-month outcome, and resource use of EM-PTCA in high-risk AMI (large
anterior or inferior, recurrent, post CABG, with pump failure), in 6 Centers
where EM-PTCA is currently performed. In the Ist semester PTCA was
attempted in 135 pts, with use of CS in 68 pts (50%): 6 women, age 56 +
10 (29-79 y). Five pts had failed iv Iysis, and 9 (13%) were in shock. CS
were implanted immediately after PTCA in all cases: the indication was a
threatening dissection or unsatisfactory balioon result in 55 pts, and elective
in 13 (19%). Vessel distribution was as follows: 36 LAD (53%), 23 RCA, 4
Cx/OM, and 5 SVG. IABP was used in 15 pts (22%) Immediate success was
achieved in 67 pts (99%), with balloons of 3.4 + 0.3 mm at 15 + 2 atm.
Multipie CS were uaed in 14 pts. (21%). Final flow was TIMI 3 and 2 in 65
and 3 ceees, respectively,and residual StenOSiSwas 12 + 4%.; pain was
absent in 60 pts, with a normal ST segment in 32 (47%). During hospitai stay
(10 + 4 d; 5-24) 6 pts (9%) had subacute CS occlusion (with redo PTCA in
3, and CABG in 2), 2 pts had vascular repair, and 5 pts (7Yo)died, due to
persistent shock in 3. Medication at discharge (61 pts) inciuded ticlopidine
alone in 40 pta (66Yo),aspirin alone in 7 pts, both in 8 pts, and antimagulants
in 6 pts. Follow-up angiographic results in this cohort will be available in Nov.
’96. /n conclusion.’CS may increase the immediate success of EM-PTCA in
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